{ "schemaVersion": "deck-intelligence.v1", "id": "019de075-e341-775b-a82c-decdaeb5c03e", "slug": "c5ed60c4cc85a094dbae2fa13cb26a34", "title": "Alkermes | Investor Presentation Deck | 37 slides", "subtitle": "Mural Oncology · 2023-10", "author": "Mural Oncology", "date": "2023-10-01 00:00:00", "pageCount": 37, "kind": "conference-presentation", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de075-e341-775b-a82c-decdaeb5c03e", "slug": "c5ed60c4cc85a094dbae2fa13cb26a34", "title": "Alkermes | Investor Presentation Deck | 37 slides", "rawTitle": "Alkermes | Investor Presentation Deck | 37 slides", "authorId": "alkermes", "authorName": "Mural Oncology", "authorDisplay": "Mural Oncology", "kind": { "slug": "conference-presentation", "label": "Conference presentation" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-10__alkermes__investor-pres__c5ed60c4.pdf", "sourceUrl": "https://www.slidebook.io/company/alkermes/presentation/c5ed60c4cc85a094dbae2fa13cb26a34/", "sourceDate": "2023-10-15 00:00:00", "presentationDate": "2023-10-01 00:00:00", "ingestedAt": "2026-04-30 22:15:15.701235+00", "status": "ready", "pageCount": 37, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "drug-manufacturers-specialty-generic", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-10__alkermes__investor-pres__c5ed60c4", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 37, "pagesIndexed": 37, "pagesWithImages": 37, "pagesWithMetadata": 37, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 170, "chartCount": 9, "metricSlides": 0, "toolMatches": 6, "documentToolMatches": 0, "frameworkMatches": 13, "arcMatches": 1, "beatMatches": 3, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "evidence": "The document follows a similar structure to the Sequoia Pitch, with sections on problem, solution, and financials.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:37:51.942369+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 8, "name": "Problem", "beatId": "3ac1c689-f5a4-4697-9836-72c6ac79bd59", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 8-9 discuss the role of cytokines in immuno-oncology and their limitations.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 35, "name": "Financials", "beatId": "62a80895-2958-4f61-acc3-5b77095f6cea", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "Slides 35-36 provide an overview of Mural Oncology's carve-out financials.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "b9e35abb-b37b-4734-a4e7-f370e28be28e", "evidence": "Slides 8-9 imply that current therapies have limitations and that Mural Oncology's solutions are needed.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cytokine therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:52.082272+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 21, "from": 20, "loop": { "name": "21_before_after", "slug": "21-before-after", "status": "active", "bestFor": "Product demos, process improvements, ROI justification", "canonId": "019dd956-6e68-73fd-a295-fe90145c2da8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison", "familyLabel": null, "categoryName": "Comparison", "categorySlug": "comparison" }, "matchId": "ba81daf0-fae5-4421-90e6-9efd4d2dbee9", "evidence": "Slides 20-21 present clinical results showing improved treatment outcomes with Nemvaleukin alfa.", "position": 1, "objective": "How does Nemvaleukin alfa improve treatment outcomes?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:52.116446+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Gantt chart", "slug": "gantt-chart", "status": "active", "bestFor": null, "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3692e6a7-c0c5-48e2-a7f8-3fe923375730", "evidence": "chart/bar-horizontal: Pipeline Gantt chart showing clinical phases", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:27.572573+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "fbbc1b65-8c8a-4bb8-ab53-21ecfa3d0f83", "evidence": "diagram/hub-spoke: Other Mechanistic Combinations", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:26.917646+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "115d45d3-67e5-4bad-9ef2-223075b8b033", "evidence": "type: section_divider", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:27.047836+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "dc9ef978-7da2-4e2f-8175-40a0c1d9d17d", "evidence": "slide type is section_divider with headline", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:39:13.191855+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c4982d91-8a2a-43a5-af85-798753a543ff", "evidence": "slide type is executive_summary with list/numbered and source-note", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:39:13.315078+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Storytelling: the closing ask", "slug": "closing-ask", "status": "active", "bestFor": null, "canonId": "019df269-24e0-70ab-8dd9-983832c1c665", "version": 1, "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d", "description": "The single most important slide in the deck — after the cover. The final", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "8dc5ed1c-142d-4bf2-aea4-c9e08bb17563", "evidence": "slide type is closing_ask with headline and image/logo", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:39:13.401599+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "a48da84e-3c0b-4eac-b4f0-88a7fb308a3c", "evidence": "Visual timeline of clinical development phases for multiple programs.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:30:33.723+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "gantt-chart" }, { "matchId": "d1b9b1ec-a92e-4f2f-a24d-f8b447ccb5fe", "evidence": "The table maps specific technical challenges (problems) to protein engineering solutions (fixes).", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:33.572+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "before-after-bridge" }, { "matchId": "a8880e9b-2313-4d40-af4d-53ca0a262569", "evidence": "Vertical stage gate flow diagram", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "process" }, { "matchId": "6df56bcd-8b16-450a-a477-155c131ddd08", "evidence": "The slide contrasts the mechanism of Nemvaleukin (left) with the problematic mechanism of IL-2 (right) to show differentiation.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:34.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "before-after-framing" }, { "matchId": "0f61c63e-b495-46d2-a1e6-cb864a146716", "evidence": "The slide uses a structured table to present clinical trial data.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:39.776+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "list-presentation" }, { "matchId": "7b6caca2-d019-4b3d-ae5c-4d0ca718c144", "evidence": "Flowchart showing progression from Part A to Parts B and C", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:34.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "frameworkName": "process" }, { "matchId": "8b6e5c11-7751-49cc-aa13-9eac664ae47a", "evidence": "Visual comparison of patient condition before and after treatment", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "before-after-framing" }, { "matchId": "11cbaa66-4de5-40fb-a100-c36a132c6c4e", "evidence": "Standardized representation of trial arms, randomization, and dosing schedules.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:35.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "clinical-trial-design" }, { "matchId": "15106752-6ac8-4946-8927-6cbce04b3c7b", "evidence": "The 'Other Mechanistic Combinations' section uses a central node with surrounding nodes.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:35.481+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "hub-spoke" }, { "matchId": "b32def3e-44a9-411d-a890-241b5fe1adad", "evidence": "Shows the 'before' state (IL-18BP-rich TME) and the 'after' state (Ideal interaction) to explain the problem and solution.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:36.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "before-after-bridge" }, { "matchId": "5193beec-9776-47a4-82df-c2cb15f644eb", "evidence": "Visual comparison of current challenge (IL-18 inhibition) and proposed solution (IL-18v) with a bridge arrow.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:30:36.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "before-after-bridge" }, { "matchId": "e7698d95-2cbb-4fdf-b1d9-f816e477e556", "evidence": "The slide depicts a sequential mechanism of action flow.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:37.253+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "frameworkName": "process" }, { "matchId": "4d7b409b-f4dc-48e8-bddc-54079667485a", "evidence": "Mention of separation into a new, independent publicly traded company via a spin-off", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:38.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "breakup-spinoff" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/4SGQR6LqaMYx9lmNosII2IL4r74MTSKu5uyFcFWKfiA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jNWVkNjBjNGNjODVhMDk0ZGJhZTJmYTEzY2IyNmEzNC9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 11, "componentCount": 3, "textChars": 59, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:31.632+00", "seconds": 2.067, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/1", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-1", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.3, "x": 0.65, "y": 0.22 }, "kind": "image", "text": "Mural Oncology logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:31.632+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1c5e8c4-ac04-48d5-9813-b459b2383563", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.55 }, "kind": "paragraph", "text": "October 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:31.632+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9233ca4d-c7f1-40b7-a33b-d161fc1221c9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.05, "y": 0.35 }, "kind": "title", "text": "MURAL ONCOLOGY INVESTOR CALL", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:31.632+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e11fc767-e4b0-41ce-9aea-dccefe9cf950", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/_QR5pTvshvOA8iSYsmPlNgeg78nGCopNLw0LjHyTLbI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jNWVkNjBjNGNjODVhMDk0ZGJhZTJmYTEzY2IyNmEzNC9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/ozrFYpR23ySjHPbVUKULzPdzzIz9qD6yuNpQLUxpGKs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jNWVkNjBjNGNjODVhMDk0ZGJhZTJmYTEzY2IyNmEzNC9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/QNC8HVEToQt97BnYFGzQ-IBoFbLNHuN1zhYBg_hsWjw/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jNWVkNjBjNGNjODVhMDk0ZGJhZTJmYTEzY2IyNmEzNC9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 14, "componentCount": 2, "textChars": 193, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:32.343+00", "seconds": 2.775, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/2", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-2", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.655, "w": 0.886, "x": 0.057, "y": 0.218 }, "kind": "disclaimer", "text": "Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:32.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1616cdd-0521-465e-8859-cfc024744b18", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.435, "x": 0.057, "y": 0.125 }, "kind": "title", "text": "Forward-Looking Statements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:32.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ac3b3e5-57d4-495f-a9a9-d6ad0d5bbdf0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 35, "componentCount": 4, "textChars": 293, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.687+00", "seconds": 5.077, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/3", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-3", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.12, "x": 0.45, "y": 0.22 }, "kind": "image", "text": "Speaker headshots", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.687+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "60c5d5ca-d1fd-45a4-8462-3b04a5f1b55c", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.65, "y": 0.2 }, "kind": "image", "text": "Mural Oncology logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.687+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ffbb69c5-dfeb-482a-b8df-8c84735462c3", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.48, "x": 0.06, "y": 0.23 }, "kind": "list", "text": "1. Executive Summary – Caroline Loew, Ph.D.\n2. Nemvaleukin Alfa – Josh Heiber, Ph.D. & Jessicca Rege, Ph.D.\n3. Additional Pipeline Programs – Mark Whitmore, Ph.D. & Josh Heiber, Ph.D.\n4. Financial Overview – Caroline Loew, Ph.D.\n5. Question and Answer", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.687+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb41ef5c-0f16-47c1-93f9-b6614b0e0431", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.16, "x": 0.06, "y": 0.12 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.687+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "95aea974-571e-4c5c-a660-e8345d0cadec", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 2, "textChars": 42, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:32.439+00", "seconds": 2.373, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/4", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-4", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.3, "x": 0.65, "y": 0.22 }, "kind": "image", "text": "MURAL ONCOLOGY", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:32.439+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8e5aaded-786e-4629-ad21-f2ec9b1c0baf", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.47, "x": 0.06, "y": 0.31 }, "kind": "title", "text": "SECTION 1: EXECUTIVE SUMMARY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:32.439+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9943cef-b81e-4951-8ae8-1b14d38fd3a7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "setup", "title": "The slide uses a numbered list format to present five key highlights about the company's spin-off status, cytokine portfolio, and specific drug program progress", "function": "summarize", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 3, "textChars": 1491, "nDataPoints": 0, "notes": "The slide uses a numbered list format to present five key highlights about the company's spin-off status, cytokine portfolio, and specific drug program progress.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:33.044+00", "seconds": 2.851, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/5", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-5", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.9, "x": 0.06, "y": 0.23 }, "kind": "list", "text": "1. Mural Oncology is the oncology business of Alkermes plc; Mural Oncology is expected to be separated into a new, independent publicly traded company via a spin-off in 4Q 2023. Two key data readouts anticipated within 18 months\n2. Portfolio of novel, investigational cytokines engineered to optimize the “known knowns” of native interleukins – retain their high potency while potentially overcoming their low tolerability\n3. Nemvaleukin is an intrinsically active, stable fusion protein which does not degrade into native-IL-2 and is designed to selectively bind to the intermediate-affinity IL-2 receptor, enabling a potentially enhanced therapeutic window\n4. Nemvaleukin has generated compelling clinical data to date, with durable responses¹ in monotherapy and in PD-1 combination across a range of tumor types. Exploring alternative dosing regimens. ARTISTRY-6 and ARTISTRY-7 readouts both expected in 1Q 2025²\n5. IL-18 and IL-12 programs in preclinical development with potentially differentiated therapeutic properties and leveraging advanced protein engineering capabilities. Candidate nominations expected in 2024", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.044+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4bd8788b-0709-428c-8a19-7c41f7f858e6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.06, "y": 0.87 }, "kind": "source-note", "text": "1. Durable response defined as a response with a duration that exceeds the response generally observed with standard of care treatment; in the context of high unmet disease states such as mucosal melanoma and platinum-resistant ovarian cancer (“PROC”), a response that exceeds six months is considered durable\n2. Subject to patient enrollment", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.044+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a8409b6-4e10-46d9-9acc-3a7eb61e2a07", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.42, "x": 0.06, "y": 0.12 }, "kind": "title", "text": "Mural Oncology - Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.044+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f25125e7-80c7-48fd-982a-4487a60f7c1f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "resolution", "title": "The slide uses a Gantt-style chart to map drug development stages across different indications.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 5, "textChars": 247, "nDataPoints": 0, "notes": "The slide uses a Gantt-style chart to map drug development stages across different indications.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:33.723+00", "seconds": 3.475, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/6", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-6", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.88, "x": 0.06, "y": 0.22 }, "kind": "chart", "text": "Pipeline Gantt chart showing clinical phases", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.723+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fe951da-f5aa-4dcc-9d32-676057c633aa", "parentComponentId": null }, { "bbox": null, "kind": "framework", "text": "Gantt chart representation of clinical pipeline", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.723+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9192c87-8c56-414b-857c-aa3170748ee2", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.06, "y": 0.91 }, "kind": "source-note", "text": "1. Subject to patient enrollment", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.723+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3df6f784-2395-47ca-bf54-0885011e4bee", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.3, "x": 0.07, "y": 0.96 }, "kind": "subtitle", "text": "Abbrev.: IV: intravenous; SC: subcutaneous; LFIV: less frequent IV dosing", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.723+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "08779da1-60e2-49ef-aae6-11aa26994873", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.06, "y": 0.12 }, "kind": "title", "text": "Pipeline Overview – Milestone Rich Near-Term Future", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.723+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca9c5ba5-0976-44b2-8b0b-1cda2fbddc48", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Gantt chart", "slug": "gantt-chart", "status": "active", "bestFor": null, "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3692e6a7-c0c5-48e2-a7f8-3fe923375730", "evidence": "chart/bar-horizontal: Pipeline Gantt chart showing clinical phases", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:27.572573+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "a48da84e-3c0b-4eac-b4f0-88a7fb308a3c", "evidence": "Visual timeline of clinical development phases for multiple programs.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:30:33.723+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "setup", "title": "The slide lists names, titles, and previous company affiliations for both the Board and Management Team.", "function": "introduce_nominees", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "introduce_nominees", "functionCanon": { "name": "Introduce nominees", "slug": "introduce_nominees", "status": "active", "canonId": "019de52d-1833-77fe-ac47-5f26d823a84a", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 85, "componentCount": 20, "textChars": 759, "nDataPoints": 0, "notes": "The slide lists names, titles, and previous company affiliations for both the Board and Management Team.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:36.221+00", "seconds": 5.814, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/7", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-7", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.45, "x": 0.51, "y": 0.87 }, "kind": "disclaimer", "text": "Board members other than Dr. Loew who is currently a board member, expected to serve upon effectiveness of Registration of Form 10. Management expected to serve upon completion of separation", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6727a9f4-de6f-4677-b4c9-a57ded63196c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.06, "x": 0.06, "y": 0.415 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0777bcec-23c7-4131-a6b1-986486de5582", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.06, "x": 0.06, "y": 0.805 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13192673-529e-4ec3-bbcf-cee85217f8fd", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.06, "x": 0.51, "y": 0.285 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "389e5bee-7a8d-463c-9be9-2ce2123473a3", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.06, "x": 0.51, "y": 0.415 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48954a50-8adf-4d17-aa34-93e0a3911d37", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.06, "x": 0.06, "y": 0.285 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b7a0eb4-e704-47b9-ab36-a8897bd726d7", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.06, "x": 0.06, "y": 0.545 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7f322f39-9426-44d8-b664-e16181cc4975", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.06, "x": 0.51, "y": 0.545 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "adfd1a30-470a-4bed-91ca-1003be7d9d31", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.06, "x": 0.06, "y": 0.675 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd358e66-cc03-469d-a043-d1e75d48ed7c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.58, "y": 0.425 }, "kind": "paragraph", "text": "Vicki Goodman, M.D. – CMO\nExelixis, Merck, BMS", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d980d2c-a203-40d9-8b3d-da07b5aa676a", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.13, "y": 0.295 }, "kind": "paragraph", "text": "Susan Altschuller, Ph.D., MBA\nCerevel, Immunogen, Alexion, Bioverativ, Biogen", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ec9409f-f5cd-4b15-b62c-03c563bac9b7", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.13, "y": 0.815 }, "kind": "paragraph", "text": "Caroline Loew, Ph.D.\nGlympse Bio, BMS, Merck, PhRMA", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12c783c4-1927-4b73-ba3d-3648a27b02d5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.58, "y": 0.295 }, "kind": "paragraph", "text": "Caroline Loew, Ph.D. – CEO\nGlympse Bio, BMS, Merck, PhRMA", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "39e73aee-1552-42bc-9b60-0b25f3fde5a3", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.13, "y": 0.425 }, "kind": "paragraph", "text": "Francis Cuss, M.B., B.Chir., FRCP\nBMS, Schering-Plough, GSK", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "418a4273-a315-4c3b-891f-1ac7aaa5a7b2", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.13, "y": 0.685 }, "kind": "paragraph", "text": "Scott Jackson, MBA - Chairman\nCelator, Eli Lilly, Smithkline Beecham, Imclone, J&J, Eximias", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac9baa90-b867-44d6-b670-278f428ceabe", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.58, "y": 0.555 }, "kind": "paragraph", "text": "Maiken Keson-Brookes - CLO\nRubius, Synlogic, uniQure, Forum, Biogen", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb5a8c18-b457-48dc-aaf8-fdbac7f8c568", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.13, "y": 0.555 }, "kind": "paragraph", "text": "Benjamin Hickey, MBA\nMirati, Halozyme, BMS", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2035e3e-741f-49bd-a37e-97f6f68e1390", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Building World Class Board and Management Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6ddf4b6-39bf-4234-88e9-d301dd64230f", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.2, "x": 0.58, "y": 0.215 }, "kind": "title", "text": "Management Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ef0bcbc-7270-48fa-93c5-a3d5d0e895cf", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.2, "x": 0.13, "y": 0.215 }, "kind": "title", "text": "Board of Directors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "73c061c7-3f53-4f3d-a874-6848f4f32e7c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 8, "type": "tension", "title": "The diagram illustrates the interaction between T cells, tumor cells, and cytokines (IL-2, IL-12, IL-18) and the mechanism of checkpoint inhibitors.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 7, "textChars": 1207, "nDataPoints": 1, "notes": "The diagram illustrates the interaction between T cells, tumor cells, and cytokines (IL-2, IL-12, IL-18) and the mechanism of checkpoint inhibitors.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.011+00", "seconds": 3.599, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/8", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-8", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.35, "x": 0.06, "y": 0.235 }, "kind": "image", "text": "Diagram showing T cell and tumor cell interaction with cytokines and checkpoint inhibitors", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "352d921a-381d-4a1d-b729-c85f324e10e6", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.58, "x": 0.38, "y": 0.23 }, "kind": "list", "text": "Checkpoint modulation has driven the growth of the IO field - $88 billion in sales projected by 2027. Only a minority of solid tumor patients experience a response to anti-PD-(L)1 therapy. Responders to existing immunotherapies often experience disease progression.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0caa8d1d-8079-4b35-8956-720053ca4b93", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.58, "x": 0.38, "y": 0.42 }, "kind": "list", "text": "Cytokines are biologically active proteins that play an essential role in immune cell functions. In cancer, cytokines can help prime, expand, activate, and/or enhance activity of the immune system to recognize and eliminate tumor cells.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4dd4120-19cb-4290-b357-ccf66dde9b9f", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.58, "x": 0.38, "y": 0.55 }, "kind": "list", "text": "Mural Oncology focuses on optimizing immune cell activity, a key driver of immune response to cancer cells. EXPANSION: IL-2 expands tumor-killing immune cells. RESTORATION: IL-18 reinvigorates T cell exhaustion. ACTIVATION: IL-12 drives pro-inflammatory responses.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dabe5f89-6ec4-4836-a7a4-80758b424f99", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.58, "x": 0.38, "y": 0.78 }, "kind": "paragraph", "text": "Mural Oncology’s engineered cytokines may lead to new therapies for significant patient populations where checkpoint inhibitors failed to achieve a response or had a limited response", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a743f78-7f19-4f18-b3f3-68196d92592d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "Extracted from Lei Q, et al. Front. Cell Dev. Biol. 2020;8:00672. 1. GlobalData Thematic Research: Immuno-Oncology", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b832bceb-1665-4166-8f2d-ccc778bdd8ec", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Cytokines Play an Important Role in Immuno-Oncology (IO)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13d78fb2-e7e6-4ed7-a329-a05b1fdf98cc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Problem", "beatId": "3ac1c689-f5a4-4697-9836-72c6ac79bd59", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 8-9 discuss the role of cytokines in immuno-oncology and their limitations.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "b9e35abb-b37b-4734-a4e7-f370e28be28e", "evidence": "Slides 8-9 imply that current therapies have limitations and that Mural Oncology's solutions are needed.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cytokine therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:52.082272+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "setup", "function": "present_framework", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 3, "textChars": 368, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:33.116+00", "seconds": 2.639, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/9", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-9", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.238 }, "kind": "list", "text": "Our Deep Understanding of Biology: Modulate multiple immune pathways, explore treatment regimens, focus on targets with strong biologic rationales.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.116+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a6e1b8f-db01-41dc-af12-f47989097c21", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.558 }, "kind": "list", "text": "Protein Engineering Capabilities: Apply solutions for binding selectivity/tumor-targeting, design cytokines to overcome negative effects, goal is a portfolio of molecules.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.116+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e94382ca-e3b6-4c69-b4ba-a9fdc2e74f04", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.75, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Leveraging Core Competencies to Optimize Cytokines", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.116+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7146f219-dbdb-461d-b324-4fd00dd277d5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Problem", "beatId": "3ac1c689-f5a4-4697-9836-72c6ac79bd59", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 8-9 discuss the role of cytokines in immuno-oncology and their limitations.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 8, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "b9e35abb-b37b-4734-a4e7-f370e28be28e", "evidence": "Slides 8-9 imply that current therapies have limitations and that Mural Oncology's solutions are needed.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cytokine therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:52.082272+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "setup", "title": "The slide uses a problem-solution framework to justify the engineering approach for each therapeutic program.", "function": "present_solution", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 443, "nDataPoints": 0, "notes": "The slide uses a problem-solution framework to justify the engineering approach for each therapeutic program.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:33.572+00", "seconds": 3.055, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/10", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-10", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.88, "x": 0.06, "y": 0.93 }, "kind": "disclaimer", "text": "1. Intrinsically active stable, not degraded fusion protein, sterically occluded from binding to the high-affinity IL-2R. Abbrev.: Tregs: regulatory T cells; rhIL: recombinant human IL; IL-2R: IL-2 receptor; IL-2Ra: IL-2R alpha, IL-18BP: IL-18 binding protein", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.572+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6e631cd-ddb3-4497-92d4-3b6cf293e26e", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.08, "x": 0.21, "y": 0.35 }, "kind": "image", "text": "Molecular diagrams for IL-2, IL-18, and IL-12", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.572+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "521a5ecf-0745-46f0-bb27-cb45802be3f8", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.88, "x": 0.06, "y": 0.25 }, "kind": "table", "text": "Program, Technical challenge, Protein engineering solution", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.572+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "403a4724-91ef-4400-aa68-9d7b66dbdd4e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.88, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "Leveraging Core Competencies: IO Programs Grounded in Strong Scientific Rationale", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.572+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df0b7816-1474-41c0-9e82-9af82c55802a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "d1b9b1ec-a92e-4f2f-a24d-f8b447ccb5fe", "evidence": "The table maps specific technical challenges (problems) to protein engineering solutions (fixes).", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:33.572+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "before-after-bridge" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 11, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 2, "textChars": 41, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:32.745+00", "seconds": 2.178, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/11", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-11", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.3, "x": 0.65, "y": 0.2 }, "kind": "image", "text": "MURAL ONCOLOGY", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:32.745+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05ad373f-13a1-47d8-8b82-c6b042c63050", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.43, "x": 0.06, "y": 0.31 }, "kind": "title", "text": "SECTION 2: NEMVALEUKIN ALFA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:32.745+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e0cacc0b-174f-4e2f-8691-59641b269050", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 12, "type": "setup", "title": "Uses a vertical process flow diagram to represent development stage gates.", "function": "present_framework", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 8, "textChars": 894, "nDataPoints": 0, "notes": "Uses a vertical process flow diagram to represent development stage gates.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.051+00", "seconds": 3.371, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/12", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-12", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.09, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Development Stage Gates", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1579197-c82f-4fca-9731-9c73bb53bfa0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.05, "y": 0.95 }, "kind": "disclaimer", "text": "Abbrev: RCC: Renal Cell Carcinoma; CPI: Checkpoint Inhibitor; FDA: Food and Drug Administration; MHRA: Medicines and Healthcare products Regulatory Agency; ILAP: Innovative Licensing and Access Pathway. IL-2R: IL-2 receptor; rhIL-2: recombinant human IL-2; IL-2Ra: IL-2R alpha", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fbb899b-1182-4540-9305-c6d68d92a90d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.08, "x": 0.86, "y": 0.23 }, "kind": "image", "text": "Nemvaleukin logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b6ef060-4d52-45a1-8a70-98713efbe99e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.82, "x": 0.13, "y": 0.22 }, "kind": "list", "text": "Novel Design: Fusion protein of IL-2 and IL-2Ra, designed to expand therapeutic benefits while mitigating toxicities; stable and active.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "07e6ecf8-9479-45a7-a6e2-0d785a977964", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.82, "x": 0.13, "y": 0.38 }, "kind": "list", "text": "Pharmacological PoC: Dose-dependent expansion of NK and CD8+ T cells; minimal non-dose dependent effects on Tregs.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12e42de3-038f-440b-8959-284116f5d1db", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.82, "x": 0.13, "y": 0.68 }, "kind": "list", "text": "Potential Approval and Indication Expansion: Near-term data readouts (PROC, Mucosal Melanoma); focus on new dosing and indications.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1cccf05a-f815-4eca-904e-0d6a1df34111", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.82, "x": 0.13, "y": 0.52 }, "kind": "list", "text": "Clinical Validation: Monotherapy responses in melanoma/RCC; combination with pembrolizumab; IV QDx5 dosing.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "85aefb7e-baec-4eb9-85fa-b9dda00b4243", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.75, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "Nemvaleukin: A Disciplined and Systematic Approach to Developing an Engineered IL-2 Variant", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5380921d-0aa7-4e26-ad09-f022cea8c5a8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "a8880e9b-2313-4d40-af4d-53ca0a262569", "evidence": "Vertical stage gate flow diagram", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:34.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "process" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 13, "type": "setup", "title": "Uses a before-after-framing style comparison to illustrate the mechanism of action differentiation.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 4, "textChars": 316, "nDataPoints": 0, "notes": "Uses a before-after-framing style comparison to illustrate the mechanism of action differentiation.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.242+00", "seconds": 3.517, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/13", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-13", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.42, "w": 0.94, "x": 0.03, "y": 0.5 }, "kind": "framework", "text": "Mechanism of action comparison between Nemvaleukin and IL-2", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "256cd280-a996-4fb7-845d-79fb2f212e28", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.56, "x": 0.22, "y": 0.22 }, "kind": "image", "text": "Molecular structure comparison of Nemvaleukin and IL-2/IL-2Ra complex", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8280877f-a16a-4fb6-80fb-f8965b7d89eb", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.18, "x": 0.04, "y": 0.235 }, "kind": "list", "text": "Intrinsically active stable fusion protein; Does not require metabolic or proteolytic conversion; Does not degrade to native IL-2", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d72a9024-93c6-4fb1-bd4f-cbe6cd8b99e3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.88, "x": 0.06, "y": 0.12 }, "kind": "title", "text": "Nemvaleukin Meaningfully Differentiated from High-Dose IL-2", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c360c053-34aa-40e3-80c9-78fdd5aa3d8c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6df56bcd-8b16-450a-a477-155c131ddd08", "evidence": "The slide contrasts the mechanism of Nemvaleukin (left) with the problematic mechanism of IL-2 (right) to show differentiation.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:34.242+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "before-after-framing" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 14, "type": "analysis", "title": "The chart displays longitudinal data for three cell types over 35 days, highlighting the differential pharmacodynamic response.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 4, "textChars": 314, "nDataPoints": 30, "notes": "The chart displays longitudinal data for three cell types over 35 days, highlighting the differential pharmacodynamic response.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:33.339+00", "seconds": 2.331, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/14", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-14", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.35, "x": 0.6, "y": 0.38 }, "kind": "callout", "text": "CD8+ and NK cells expanded while Treg cells remained suppressed", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75a553c1-7431-468a-9857-034b45bec18e", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.55, "x": 0.05, "y": 0.22 }, "kind": "chart", "text": "Immune cell expansion Cycles 1 - 2", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "61d313a7-3420-4eb6-89d4-1bf13a492603", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.05, "y": 0.92 }, "kind": "disclaimer", "text": "Nemvaleukin data are from the 6 µg/kg cohort in Part A of the study. For fold change plots, data are mean + SE (N=10). For time course plot, data are mean + SD (N=12).", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc5fb71f-82e5-4580-a587-32bc74fe1bd5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Clinical Pharmacodynamic Effects of Nemvaleukin1,2", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:33.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ce5fb04-3ddb-4033-abc3-6731a924310a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 15, "type": "setup", "title": "The table uses a structured approach to categorize clinical trials into Foundational, Alternative Dosing, and Registrational enabling.", "function": "present_framework", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 3, "textChars": 207, "nDataPoints": 0, "notes": "The table uses a structured approach to categorize clinical trials into Foundational, Alternative Dosing, and Registrational enabling.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:39.776+00", "seconds": 8.647, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/15", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-15", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.3, "x": 0.08, "y": 0.96 }, "kind": "source-note", "text": "Abbrev.: IV: Intravenous; LFIV: Less frequent IV; SC: Subcutaneous", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:39.776+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0c76fa4-1cd4-4fb1-bbca-3d51d8332e68", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.233 }, "kind": "table", "text": "Type of Clinical Trial, Trial Name / Phase, Tumor Types, Dosing, Mono or Combo? Status", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:39.776+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ebe419d4-920d-4218-ab88-277c7b0f0979", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.88, "x": 0.06, "y": 0.12 }, "kind": "title", "text": "Nemvaleukin: Deliberate and Focused Development Program", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:39.776+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7273549e-5ad3-4550-8457-0929129be807", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0f61c63e-b495-46d2-a1e6-cb864a146716", "evidence": "The slide uses a structured table to present clinical trial data.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:39.776+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "list-presentation" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 16, "type": "setup", "title": "The slide uses a process flow diagram to illustrate the progression of the clinical trial cohorts.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 4, "textChars": 694, "nDataPoints": 12, "notes": "The slide uses a process flow diagram to illustrate the progression of the clinical trial cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.391+00", "seconds": 3.18, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/16", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-16", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Dose Escalation to Dose Expansion flow", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e37c07b1-1903-4585-bb70-8692de138da0", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.88, "x": 0.06, "y": 0.84 }, "kind": "disclaimer", "text": "NCTO2799095. 1. Patients from Parts A and B could roll over to Part C upon progression or stable disease (after >= 4 cycles) on monotherapy. 2. Nemvaleukin daily Q5D, then off treatment for 9 days (cycle 1) or 16 days (cycle 2+). 3. ORR assessed by investigator (RECIST v1.1). 4. Nemvaleukin 3 ug/kg/d in C1-C4, 6 ug/kg/d in C5-C7. PD-(L)1 approved/unapproved indication based on FDA prescribing information and may have changed over time.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "08acb452-5d45-4260-8b3e-28bd20b8651a", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.28, "x": 0.06, "y": 0.58 }, "kind": "paragraph", "text": "Median Prior lines of therapy: Part B Monotherapy Melanoma: 3; Part B Monotherapy RCC: 2; Part C Combination therapy: 3", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a1aa0d0-fdd1-46ed-9356-fd3ee0b8e013", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.75, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "ARTISTRY-1: First-In-Human Study of IV Nemvaleukin Global, Multicenter, Open-Label Phase 1/2 Study", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5f4e30b-15c3-4e9a-b8dd-6ae0e50f894d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "7b6caca2-d019-4b3d-ae5c-4d0ca718c144", "evidence": "Flowchart showing progression from Part A to Parts B and C", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:34.391+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "frameworkName": "process" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 17, "type": "analysis", "title": "The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.", "function": "analyze_data", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 4, "textChars": 426, "nDataPoints": 16, "notes": "The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.334+00", "seconds": 3.057, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/17", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-17", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.65 }, "kind": "list", "text": "Summary of key safety findings for monotherapy and combination therapy.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18c35005-79a1-4c39-9d8b-c1ed02fff9f3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.93 }, "kind": "source-note", "text": "1. Data as of March 27, 2023. Abbrev.: AE: Adverse Event; TRAE: Treatment Related Adverse Event; AST: aspartate aminotransferase; RCC: Renal Cell Carcinoma", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2125c9b0-3375-481b-9b72-a8f099719950", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.9, "x": 0.05, "y": 0.22 }, "kind": "table", "text": "Comparison of adverse events between monotherapy and combination therapy cohorts.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d017386e-7870-44b4-9128-3b32830c1bb4", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Nemvaleukin’s Adverse Event Profile in ARTISTRY-1 Was Consistent with Our Expectations Based on its Mechanism of Action", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.334+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "658fe09a-8be1-491b-b456-5fd371e756dc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 18, "type": "analysis", "title": "The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.", "function": "analyze_data", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 5, "textChars": 574, "nDataPoints": 34, "notes": "The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.968+00", "seconds": 3.357, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/18", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-18", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.4, "x": 0.55, "y": 0.2 }, "kind": "image", "text": "ARTISTRY-1 (IV Nemvaleukin) Objective Response Summary map", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.968+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3830fb6c-0fcb-450a-93d4-85638d3ecc61", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.45, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "Monotherapy activity (IV) in prior anti-PD-(L)1 treated melanoma and renal cell carcinoma: 10 Objective responses (10 PRs (7 confirmed))", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.968+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8944edb8-b8e4-43f0-908b-9e38c35fcfd4", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.05, "y": 0.5 }, "kind": "list", "text": "Combination activity (IV) with pembrolizumab in a range of tumor types: 24 Objective responses (5 CRs, 14 PRs, 5uPRs)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.968+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8d961aa-1701-4cf0-9b07-8a9e6c09b543", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "Patients achieved SD (*acral), PR (*RCC), and PD (#RCC) on nemvaleukin monotherapy, rolled over to combination therapy and achieved PR. Data as of March 27, 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.968+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f5b0be7-7ada-4812-89dc-d3d4604357bb", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "ARTISTRY-1: IV Nemvaleukin Demonstrated Durable and Deepening Responses in High Unmet Need Populations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.968+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9e65112-2218-43aa-887a-696ac5fcd888", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 19, "type": "analysis", "title": "Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 253, "nDataPoints": 14, "notes": "Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.447+00", "seconds": 2.62, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/19", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-19", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.5, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Swimmer plot showing duration of treatment for individual patients", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.447+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "226444dd-96ec-436b-ab54-d60ea986023c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.1, "x": 0.85, "y": 0.9 }, "kind": "source-note", "text": "Data cut off Mar 27 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.447+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eddddaa4-da73-45e5-b59f-87e883e22431", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.38, "x": 0.58, "y": 0.22 }, "kind": "table", "text": "Summary table of best overall response (CR, PR, SD, PD, ORR, DCR, Median DOR)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.447+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9c47226b-57d2-4f67-b302-aab0c62e4690", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "ARTISTRY-1: IV Nemvaleukin Combination Responses with Pembrolizumab (Part C, Cohort 1)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.447+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ec81872-db4a-4258-8853-327672e1ff94", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 20, "type": "evidence", "title": "The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.", "function": "illustrate_case", "rawType": "before_after", "block": null, "metadata": { "slideType": "before_after", "slideTypeCanon": { "name": "Before / after", "slug": "before_after", "status": "active", "canonId": "019de52d-11fd-771e-bb45-e27f849bc560", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 7, "textChars": 360, "nDataPoints": 4, "notes": "The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:35.433+00", "seconds": 3.513, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/20", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-20", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "diagram", "text": "Timeline of treatment from Feb 2020 to Apr 2022", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "555b26c2-196b-4f39-ba03-f4701d89fa30", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.7, "y": 0.45 }, "kind": "image", "text": "Cycle 24 CT scan", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63f4340a-d426-472f-8758-38fa9eb228bc", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.45, "y": 0.45 }, "kind": "image", "text": "Cycle 4 CT scan", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8d530a3-1366-4faa-93ae-b5644c0bd25b", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.2, "y": 0.45 }, "kind": "image", "text": "Baseline CT scan", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7b28ade-02ce-4218-833b-0525928e7661", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.18, "x": 0.06, "y": 0.29 }, "kind": "list", "text": "Diagnosed in 2008 with high-grade serous ovarian cancer; 2 prior lines of therapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a0f97413-bc23-4a0c-9016-802b44799cea", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.87 }, "kind": "source-note", "text": "1 Response per RECIST v1.1; 2 Death unrelated to TX, subject remained in CR thru final response assessment", "attrs": { "numbered": true }, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e3a355f-8195-48b2-9ef4-20fbdb0faccf", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Complete Response in 83-Year-Old Patient with Platinum-Resistant Ovarian Cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a9ee0f12-81fc-47df-a049-fc3b2eee450b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "8b6e5c11-7751-49cc-aa13-9eac664ae47a", "evidence": "Visual comparison of patient condition before and after treatment", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:30:35.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "before-after-framing" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Solution", "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 21, "from": 20, "loop": { "name": "21_before_after", "slug": "21-before-after", "status": "active", "bestFor": "Product demos, process improvements, ROI justification", "canonId": "019dd956-6e68-73fd-a295-fe90145c2da8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison", "familyLabel": null }, "matchId": "ba81daf0-fae5-4421-90e6-9efd4d2dbee9", "evidence": "Slides 20-21 present clinical results showing improved treatment outcomes with Nemvaleukin alfa.", "position": 1, "objective": "How does Nemvaleukin alfa improve treatment outcomes?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:52.116446+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "analysis", "title": "Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.", "function": "analyze_data", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 5, "textChars": 941, "nDataPoints": 32, "notes": "Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:35.339+00", "seconds": 3.297, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/21", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-21", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.45, "x": 0.05, "y": 0.2 }, "kind": "chart", "text": "Swimmer plot showing duration of treatment for individual patients", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d74c510-20c5-4285-bb2a-f3948507a5d9", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.4, "x": 0.55, "y": 0.7 }, "kind": "list", "text": "All responders had been on prior CPI therapy and progressed; FDA Orphan Drug and Fast Track designations; Data supported design of ARTISTRY-6 study", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81f1110b-05bd-403a-9cbe-3030cdd8b884", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Abbrev: adj: adjuvant; ATEZO: atezolizumab; BIN: binimetinib; CBP: carboplatin; CI: confidence interval; COB: cobimetinib; CPI: checkpoint inhibitor; CR: complete response; DAB: dabrafenib; DCR: disease control rate (CR+PR+SD); DOR: duration of response; ENCO: encorafenib; FDA: US Food and Drug Administration; IPI: ipilimumab; MV: melanoma vaccine; NA: not applicable; NIVO: nivolumab; ORR: overall response rate; PAC: paclitaxel; PD: progressive disease; PEMBRO: pembrolizumab; PR: partial response; SD: stable disease; TRAM: trametinib; TVEC: talimogene laherparepvec; VEM: vemurafenib", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "512f83a0-c810-49c8-8c23-0e7fdf19b830", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.4, "x": 0.55, "y": 0.2 }, "kind": "table", "text": "Summary table of best overall response, ORR, DCR, and DOR", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12a20305-52aa-405a-bd89-bd675f6ccd10", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "ARTISTRY-1: IV Nemvaleukin Demonstrated Monotherapy Responses in Melanoma (Part B)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.339+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56c23cb2-00e8-40a2-916c-09f48477180d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 21, "from": 20, "loop": { "name": "21_before_after", "slug": "21-before-after", "status": "active", "bestFor": "Product demos, process improvements, ROI justification", "canonId": "019dd956-6e68-73fd-a295-fe90145c2da8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison", "familyLabel": null }, "matchId": "ba81daf0-fae5-4421-90e6-9efd4d2dbee9", "evidence": "Slides 20-21 present clinical results showing improved treatment outcomes with Nemvaleukin alfa.", "position": 1, "objective": "How does Nemvaleukin alfa improve treatment outcomes?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:52.116446+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "appendix", "title": "The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.", "function": "present_framework", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 468, "nDataPoints": 0, "notes": "The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:34.734+00", "seconds": 2.596, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/22", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-22", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.35, "x": 0.32, "y": 0.3 }, "kind": "diagram", "text": "Cohort dosing diagrams for Cohorts 1, 2, and 3 showing treatment cycles and dosing frequency", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "65fa974a-6b0f-45e8-a701-dcee4d7fb552", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.05, "y": 0.34 }, "kind": "list", "text": "Key eligibility criteria: Unresectable/metastatic melanoma, prior anti-PD(L)-1, max 1 prior therapy, measurable disease, ECOG PS 0-1", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c671a53-46e4-4112-93e7-ee9f57941aa0", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.28, "x": 0.68, "y": 0.35 }, "kind": "list", "text": "Key endpoints: Primary (ORR per RECIST v1.1), Key secondary (DOR, PFS, DCR, TTR)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "82e24340-9273-4c1a-bf2b-33cd25288413", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "Footnotes regarding clinical trial registration, references, and dosing cycle exceptions.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1eb6019e-de06-47bb-be04-80c482fdfec0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "ARTISTRY-6: Phase 2 / Potentially Registrational Study for Mucosal Melanoma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:34.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0730469-7416-4b26-afe3-0188578bf6f9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 23, "type": "appendix", "title": "Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.", "function": "present_framework", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "balanced", "densityScore": 39, "componentCount": 4, "textChars": 287, "nDataPoints": 1, "notes": "Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:35.465+00", "seconds": 2.992, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/23", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-23", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Study arms and randomization flow", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ebfbfa71-f1c7-45f4-a514-9e5ce680593b", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.9, "x": 0.05, "y": 0.45 }, "kind": "list", "text": "Key eligibility criteria and endpoints", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "de921574-282c-42a2-9159-62b442455909", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "Herzog T et al. Poster presented at the Society for Gynecologic Cancers Annual Meeting (SGO), Phoenix, AZ, March 18-21, 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e837878c-fac5-4e0d-96f9-82a48c92879f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "ARTISTRY-7: Phase 3 / Potentially Registrational Study for Platinum-Resistant Ovarian Cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69ebc3f7-a147-4dac-8294-e71058129bf1", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "11cbaa66-4de5-40fb-a100-c36a132c6c4e", "evidence": "Standardized representation of trial arms, randomization, and dosing schedules.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:35.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "clinical-trial-design" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "setup", "title": "The slide uses a hub-and-spoke diagram for the mechanistic combinations.", "function": "present_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 5, "textChars": 399, "nDataPoints": 2, "notes": "The slide uses a hub-and-spoke diagram for the mechanistic combinations.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:35.481+00", "seconds": 2.905, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/24", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-24", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.3, "x": 0.66, "y": 0.33 }, "kind": "diagram", "text": "Other Mechanistic Combinations", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.481+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "157eea1a-0b71-40fd-9bd8-ffaf72f74c3f", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.05, "y": 0.33 }, "kind": "list", "text": "Platinum-Resistant Ovarian Cancer (13K Patients), Mucosal Melanoma (2K Patients)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.481+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bac26aad-8340-4815-bccb-01d79d731639", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.28, "x": 0.37, "y": 0.33 }, "kind": "paragraph", "text": "Earlier Lines of Therapy in Ovarian and Cutaneous Melanoma (40K+ patients)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.481+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "758bd83e-e2ea-445e-b9a9-301dbbcf3e0e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "1. Clarivate Epidemiology; Estimated number of patients in the U.S. and Europe. 2. Represents 3rd line PROC patients.", "attrs": { "numbered": true }, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.481+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b7f8d73-72fd-4b4f-88f5-35c59d0396a7", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Focused on Initial, Potentially Registrational Indications with Compelling Expansion Opportunities", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.481+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca32aeaf-0a1e-4f23-b9c6-441634f4ba6e", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "fbbc1b65-8c8a-4bb8-ab53-21ecfa3d0f83", "evidence": "diagram/hub-spoke: Other Mechanistic Combinations", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:26.917646+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "15106752-6ac8-4946-8927-6cbce04b3c7b", "evidence": "The 'Other Mechanistic Combinations' section uses a central node with surrounding nodes.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:35.481+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "hub-spoke" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "appendix", "title": "The slide outlines the clinical strategy for optimizing nemvaleukin dosing, referencing specific clinical trials (ARTISTRY-3 and ARTISTRY-6).", "function": "present_solution", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 3, "textChars": 411, "nDataPoints": 0, "notes": "The slide outlines the clinical strategy for optimizing nemvaleukin dosing, referencing specific clinical trials (ARTISTRY-3 and ARTISTRY-6).", "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:37.304+00", "seconds": 4.716, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/25", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-25", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.35 }, "kind": "list", "text": "Alternative dosing options being evaluated: Explore potential broad utility; Exploring less frequent IV dosing (Days 1 and 4 Q3W; Days 1 and 8 Q3W); ARTISTRY-3 and ARTISTRY-6 studies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.304+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "24011fe6-d566-471e-a4b1-ceeee4aadaff", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "list", "text": "Initial IV nemvaleukin dosing regimen: 5x daily Q3W; Dosing modeled after the currently approved high-dose rhIL-2 dosing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.304+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "442e6cd4-f35e-4e8c-b842-647f21323bbe", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Exploration of Optimal Dose Administration and Schedule for Nemvaleukin to Establish Recommended Phase 2 Dose", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.304+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7c9f15e-fee2-44b7-9caf-16e712f1e32d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 26, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 53, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:35.942+00", "seconds": 3.335, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/26", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-26", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.3, "x": 0.65, "y": 0.2 }, "kind": "image", "text": "MURAL ONCOLOGY", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.942+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a20ce65c-abb1-407a-bd20-d63fdbd257c7", "parentComponentId": null }, { "bbox": { "h": 0.37, "w": 0.45, "x": 0.063, "y": 0.315 }, "kind": "title", "text": "SECTION 3: ADDITIONAL PIPELINE PROGRAMS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:35.942+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f20918d4-564f-4eec-b748-4c0b3cb6655d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "115d45d3-67e5-4bad-9ef2-223075b8b033", "evidence": "type: section_divider", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:27.047836+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "appendix", "title": "The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatory", "function": "establish_context", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 5, "textChars": 444, "nDataPoints": 0, "notes": "The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatory functions.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:36.474+00", "seconds": 3.854, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/27", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-27", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.25, "x": 0.12, "y": 0.35 }, "kind": "diagram", "text": "IL-18 signaling pathway", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ba1957f6-697a-4e2f-b7b9-0334d9b7f4b8", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.67, "y": 0.28 }, "kind": "image", "text": "Molecular structure of IL-18 complex", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "561fea76-ba95-4d40-94bc-d19c633c3cf2", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.55, "y": 0.5 }, "kind": "list", "text": "1. Activates NK cells and antigen-experienced CD8+ T cells; 2. Re-invigorates dysfunctional T cells; 3. Matures dendritic cells (DCs)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9e6d351-df20-4ca3-9456-8d1f4ecc5ac2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.06, "y": 0.94 }, "kind": "source-note", "text": "PBMC: Peripheral Blood Mononuclear Cells. IL-18BP: IL-18 Binding Protein Source: 1) Zhou, T. et al. (2020) Nature 583:609-14. 2) Alkermes internal data", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa255239-7b05-4094-a97a-e2d9c62e6699", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.88, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "Anti-Tumor Immune-Biology of Native IL-18: A Potent Immuno-stimulator of Innate and Adaptive Immunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc9e78fb-55b7-4487-9509-f5f39956a7a7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "tension", "title": "Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 325, "nDataPoints": 10, "notes": "Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:36.118+00", "seconds": 3.115, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/28", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-28", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.3, "x": 0.08, "y": 0.4 }, "kind": "chart", "text": "Loss of IL-18 activity due to IL-18BP in vitro", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Scatter plot", "slug": "scatter", "status": "active", "canonId": "019de52d-007d-72ec-8689-c79fb78e21a2", "version": 1, "description": null }, "framework": null }, "subkind": "scatter", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48063e87-faed-475e-8897-d59fa81148fc", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.5, "x": 0.4, "y": 0.4 }, "kind": "diagram", "text": "Mechanism of IL-18BP inhibition vs ideal interaction", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8d3cd08d-c0ac-439f-9ca1-577512e9ada0", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.45, "x": 0.27, "y": 0.25 }, "kind": "list", "text": "Soluble IL-18 decoy receptor; Binds IL-18 and neutralizes interaction with IL-18Ra", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dfbfbed6-503b-4d60-909d-727e3b570cb9", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.06, "y": 0.95 }, "kind": "source-note", "text": "1. Robertson et al (2008). Clinical Cancer Research, 14(11), 3462-3469. 2. Alkermes internal data", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a32d9919-ef5d-46af-823a-f66e4979e445", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.06, "y": 0.12 }, "kind": "title", "text": "Native IL-18 is Limited by IL-18 Binding Protein", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5a59a8f-ed12-40dc-b537-b25458ce0d39", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b32def3e-44a9-411d-a890-241b5fe1adad", "evidence": "Shows the 'before' state (IL-18BP-rich TME) and the 'after' state (Ideal interaction) to explain the problem and solution.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:36.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "before-after-bridge" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "evidence", "title": "Uses a before-after-bridge framework to illustrate the mechanism of action for the therapeutic candidate.", "function": "propose_solution", "rawType": "before_after", "block": null, "metadata": { "slideType": "before_after", "slideTypeCanon": { "name": "Before / after", "slug": "before_after", "status": "active", "canonId": "019de52d-11fd-771e-bb45-e27f849bc560", "version": 1, "description": null }, "function": "propose_solution", "functionCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-185b-74e9-bdfd-ea8cf318563f", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 6, "textChars": 398, "nDataPoints": 0, "notes": "Uses a before-after-bridge framework to illustrate the mechanism of action for the therapeutic candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:36.462+00", "seconds": 3.172, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/29", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-29", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.32, "x": 0.05, "y": 0.25 }, "kind": "callout", "text": "Challenge to IL-18", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c6b17bb-7ef7-4e22-8387-f424dfa83dba", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.56, "x": 0.39, "y": 0.25 }, "kind": "callout", "text": "Mural Solution: design IL-18 variant resistant to IL-18BP", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5df25c4c-058f-4237-92d8-2d2ffe95216b", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.63, "x": 0.09, "y": 0.38 }, "kind": "image", "text": "Diagram showing IL-18 inhibited by IL-18BP vs engineered IL-18v avoiding IL-18BP", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb30dcd5-b1fd-4d3c-a7db-66cac7c50f3e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.65, "y": 0.52 }, "kind": "list", "text": "1. Resist IL-18 neutralization by immune checkpoint IL-18BP\n2. Retain and optimize IL-18 activity", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c992cc6-3324-486f-a042-975dc5de3ea0", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.12, "x": 0.28, "y": 0.78 }, "kind": "source-note", "text": "Internal expertise in protein engineering", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "132623aa-87dc-475d-af99-27755169409e", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.88, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "Mural Oncology IL-18 Engineering: Resist IL-18BP Checkpoint to Unleash the Therapeutic Potential of IL-18", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ff9aa7a-b1ce-409b-9ffd-0914c304f094", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "5193beec-9776-47a4-82df-c2cb15f644eb", "evidence": "Visual comparison of current challenge (IL-18 inhibition) and proposed solution (IL-18v) with a bridge arrow.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:30:36.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "before-after-bridge" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 30, "type": "evidence", "title": "Data shows that while WT IL-18 is inhibited by IL-18BP, the variants are resistant to this inhibition.", "function": "analyze_data", "rawType": "before_after", "block": null, "metadata": { "slideType": "before_after", "slideTypeCanon": { "name": "Before / after", "slug": "before_after", "status": "active", "canonId": "019de52d-11fd-771e-bb45-e27f849bc560", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 7, "textChars": 557, "nDataPoints": 60, "notes": "Data shows that while WT IL-18 is inhibited by IL-18BP, the variants are resistant to this inhibition.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:37.407+00", "seconds": 4.094, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/30", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-30", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.6, "x": 0.35, "y": 0.215 }, "kind": "callout", "text": "*Variants with Similar or Stronger Potency vs WT IL-18 with Resistance to IL-18BP Suppression", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.407+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "931817ca-c1a5-463e-9a5a-6ece4b81fd58", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.28, "x": 0.05, "y": 0.215 }, "kind": "callout", "text": "*No Detectable Binding Between Variants and IL-18BP", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.407+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "97de8e53-ba00-491e-9bea-ae2124cad995", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.28, "x": 0.05, "y": 0.33 }, "kind": "chart", "text": "Binding kinetics (Association/Dissociation) for WT, Variant 1, and Variant 2", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.407+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5986633e-9458-4be0-8666-c3bb8b4d1728", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.35, "y": 0.33 }, "kind": "chart", "text": "Potency assay for Variant 1 vs WT with/without IL-18BP", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.407+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca83374f-6b38-4511-91a0-2f35ab8235dd", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.68, "y": 0.33 }, "kind": "chart", "text": "Potency assay for Variant 2 vs WT with/without IL-18BP", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.407+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb5ae8c6-9e54-4164-b5d1-8dfa7ea4d2dc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "Note: No detectable binding between variants and hIL-18BP hIL18BP tested up to 1µM. *Alkermes Internal Data", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.407+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75976b10-6907-4ddd-9a47-ae6f35f2c1f7", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Mural Variants Do Not Bind IL-18BP in Preclinical Studies: Excellent Potency with Maximal Resistance to IL-18BP Inhibition", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.407+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c5d1d72-8365-46d3-b5cf-1f7536bc376f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "tension", "title": "The slide uses a diagram to illustrate the activation of immune cells (NKT, NK, CD4, CD8) by IL-12, leading to IFN-gamma production and subsequent downstream ef", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 4, "textChars": 929, "nDataPoints": 0, "notes": "The slide uses a diagram to illustrate the activation of immune cells (NKT, NK, CD4, CD8) by IL-12, leading to IFN-gamma production and subsequent downstream effects.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:36.417+00", "seconds": 2.767, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/31", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-31", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.4, "x": 0.55, "y": 0.2 }, "kind": "image", "text": "Diagram showing IL-12 structure and its activation of NKT, NK, CD4, and CD8 cells to produce IFN-gamma, which then influences T-cell function and ECM/angiogenesis.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.417+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "163f6920-e8b8-4e6a-8caa-fd086da09102", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.45, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "Heterodimeric protein consisting of two covalently linked subunits; Individual components, p35 and p40, are inactive. Anti-tumor efficacy observed in preclinical studies; Driven by activation of innate and adaptive immune compartments and production of IFN-y. Clinical evaluation limited by narrow therapeutic window; Severe toxicities associated with systemic exposure to IL-12 leading to a narrow therapeutic index.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.417+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "30ef5ef8-7250-4935-8fac-5a4c9e9305a9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "1. Nguyen KG et. al. Cancer Immunotherapy. Front. Immunol. October 15 2020 11:575597; 2. Vecchio MD et. al. Clin Cancer Res August 15 2007 (13) (16) 4677-4685; 3. Strauss J et. al. Clin Cancer Res January 1 2019 (25) (1) 99-109", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.417+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "55ee3e87-c775-46b2-b661-0b3dd455676f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "IL-12 is Recognized as a Highly-Potent Proinflammatory Cytokine But Clinical Utility Has Been Limited by Severe Toxicities", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.417+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ba3358b8-1cb3-4e7f-9f08-667a8b2e59c9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 32, "type": "setup", "title": "The slide uses a process flow diagram to explain the therapeutic mechanism.", "function": "present_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 520, "nDataPoints": 0, "notes": "The slide uses a process flow diagram to explain the therapeutic mechanism.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:37.253+00", "seconds": 3.236, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/32", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-32", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.76, "x": 0.12, "y": 0.2 }, "kind": "callout", "text": "Build functional IL-12 in the tumor with goals of avoiding toxicity associated with systemic exposure and maximizing the IL-12 therapeutic window", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.253+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "351ee140-cdc0-455d-bde1-a34472a6b5af", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "diagram", "text": "Mechanism of action flow from subunit administration to in situ assembly", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.253+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4ccdecb-b5c7-4bd2-8411-1b2b87a3db27", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.23, "y": 0.82 }, "kind": "list", "text": "Designed to reduce systemic exposure to functional IL-12, thereby potentially reducing associated toxicities\nTargeted accumulation of functional IL-12 in the tumor may improve anti-tumor activity", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.253+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f4461f7e-210c-41e2-95ab-94d66742cdd5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Mural's Approach: Tumor Site-Specific Assembly of Functional IL-12 Designed to Limit Systemic IL-12 Exposure", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:37.253+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b9c1419-7451-4d70-b4e2-698475f3251c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e7698d95-2cbb-4fdf-b1d9-f816e477e556", "evidence": "The slide depicts a sequential mechanism of action flow.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:30:37.253+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 33, "type": "setup", "title": "Includes a bar chart showing dose-dependent PD response in a mouse model and a schematic of the split IL-12 mechanism.", "function": "present_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 5, "textChars": 389, "nDataPoints": 4, "notes": "Includes a bar chart showing dose-dependent PD response in a mouse model and a schematic of the split IL-12 mechanism.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:36.535+00", "seconds": 2.395, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/33", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-33", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.43, "x": 0.52, "y": 0.26 }, "kind": "chart", "text": "Sequential Administration of Split IL-12 Subunits Resulted in Dose-Dependent PD Response in PBMC Humanized NCG Mouse Model", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6830de3f-edd5-412d-9661-ff5d7628ad5e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.12, "x": 0.38, "y": 0.63 }, "kind": "image", "text": "Split IL-12 assembly schematic", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2a0ea85-6097-47d4-bfc2-66cdaafea542", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.5, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "1. Nguyen KG et. al. 2. Vecchio MD et. al. 3. Strauss J et. al. Source: Company internal data on file", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad93001b-bc95-41b0-b8f6-7f0307acd321", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.05, "y": 0.21 }, "kind": "table", "text": "The potential of IL-12, Key anti-tumor mechanisms, Technical challenge, Mural Oncology solution", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d42f039b-ff2e-4443-a1fc-47b88f6eff11", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Tumor-Targeted Split IL-12 Program Design", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36db8967-468b-4d2a-9828-144a61043c9f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 34, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 43, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:40.548+00", "seconds": 6.36, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/34", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-34", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.64, "w": 0.3, "x": 0.65, "y": 0.18 }, "kind": "image", "text": "MURAL ONCOLOGY", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:40.548+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f7c71412-d6e5-4e0d-9549-f80a53350929", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.47, "x": 0.06, "y": 0.31 }, "kind": "title", "text": "SECTION 4: FINANCIAL OVERVIEW", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:40.548+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2621fa00-2d85-43d8-9157-5f45a4a32702", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "dc9ef978-7da2-4e2f-8175-40a0c1d9d17d", "evidence": "slide type is section_divider with headline", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:39:13.191855+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 35, "type": "analysis", "title": "Includes a footnote regarding patient enrollment for clinical milestones.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 5, "textChars": 378, "nDataPoints": 24, "notes": "Includes a footnote regarding patient enrollment for clinical milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:36.947+00", "seconds": 2.526, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/35", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-35", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.22, "x": 0.06, "y": 0.36 }, "kind": "list", "text": "Key milestones: Candidate nominations for IL-18 and IL-12 expected in 2024; PROC top-line data readout expected 1Q 2025; Mucosal melanoma top-line data readout expected 1Q 2025", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "11dbe287-597b-4ea1-b5e1-f57a64f72e9b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.22, "x": 0.06, "y": 0.21 }, "kind": "paragraph", "text": "Mural Oncology is expected to have $200M - $300M of cash on the balance sheet upon separation", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2710cff7-3213-438f-8342-ffa18a8c36f9", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.06, "y": 0.91 }, "kind": "source-note", "text": "1. Subject to patient enrollment", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b25696e4-2fb4-4507-aa11-a0a3ea7964ea", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.65, "x": 0.29, "y": 0.22 }, "kind": "table", "text": "Operating Expenses table for 2022 and 2021", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31bc671a-213c-4349-845e-f7b0ef904b1c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.06, "y": 0.12 }, "kind": "title", "text": "Mural Oncology Carve-Out Financials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.947+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "067b5536-f6a5-4eb9-939b-90c88e84b5bf", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 35, "name": "Financials", "beatId": "62a80895-2958-4f61-acc3-5b77095f6cea", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "Slides 35-36 provide an overview of Mural Oncology's carve-out financials.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 36, "type": "setup", "title": "Uses a numbered list format to highlight key company facts.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 3, "textChars": 1484, "nDataPoints": 0, "notes": "Uses a numbered list format to highlight key company facts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:38.097+00", "seconds": 3.436, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/36", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-36", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.92, "x": 0.05, "y": 0.23 }, "kind": "list", "text": "1. Mural Oncology is the oncology business of Alkermes plc; Mural Oncology is expected to be separated into a new, independent publicly traded company via a spin-off in 4Q 2023. Two key data readouts anticipated within 18 months\n2. Portfolio of novel, investigational cytokines engineered to optimize the “known knowns” of native interleukins – retain their high potency while potentially overcoming their low tolerability\n3. Nemvaleukin is an intrinsically active, stable fusion protein which does not degrade into native-IL-2 and is designed to selectively bind to the intermediate-affinity IL-2 receptor, enabling a potentially enhanced therapeutic window\n4. Nemvaleukin has generated compelling clinical data to date, with durable responses in monotherapy and in PD-1 combination across a range of tumor types. Exploring alternative dosing regimens. ARTISTRY-6 and ARTISTRY-7 readouts expected in 1Q 2025\n5. IL-18 and IL-12 programs in preclinical development with potentially differentiated therapeutic properties and leveraging advanced protein engineering capabilities. Candidate nominations expected in 2024", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:38.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47641fa7-3902-4230-ae98-1693d163aa2b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.92, "x": 0.05, "y": 0.87 }, "kind": "source-note", "text": "1. Durable response defined as a response with a duration that exceeds the response generally observed with standard of care treatment; in the context of high unmet disease states such as mucosal melanoma and platinum-resistant ovarian cancer (“PROC”), a response that exceeds six months is considered durable\n2. Subject to patient enrollment", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:38.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fd3bb61-3387-4452-aa3a-00970ca794a9", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.4, "x": 0.06, "y": 0.12 }, "kind": "title", "text": "Mural Oncology - Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:38.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "26cc1c50-1bb5-4280-b2d9-abf396cb1306", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c4982d91-8a2a-43a5-af85-798753a543ff", "evidence": "slide type is executive_summary with list/numbered and source-note", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:39:13.315078+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "4d7b409b-f4dc-48e8-bddc-54079667485a", "evidence": "Mention of separation into a new, independent publicly traded company via a spin-off", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:30:38.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "breakup-spinoff" } ], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 35, "name": "Financials", "beatId": "62a80895-2958-4f61-acc3-5b77095f6cea", "matchId": "ff8ba9af-467f-4179-9e55-c333bbbe3c8b", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "Slides 35-36 provide an overview of Mural Oncology's carve-out financials.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 37, "type": "setup", "function": "summarize", "rawType": "closing_ask", "block": null, "metadata": { "slideType": "closing_ask", "slideTypeCanon": { "name": "Closing ask", "slug": "closing_ask", "status": "active", "canonId": "019de52d-0aa4-750f-8aa1-8d622dd99f5c", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 24, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:30:36.659+00", "seconds": 1.984, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/37", "deck": "/decks/019de075-e341-775b-a82c-decdaeb5c03e", "deckAnchor": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-37", "deckJson": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json" }, "components": [ { "bbox": { "h": 0.225, "w": 0.35, "x": 0.618, "y": 0.745 }, "kind": "image", "text": "MURAL ONCOLOGY", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.659+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48a6aab7-32e8-4abe-858c-3e5b5ed14468", "parentComponentId": null }, { "bbox": { "h": 0.075, "w": 0.284, "x": 0.358, "y": 0.348 }, "kind": "title", "text": "THANK YOU!", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:30:36.659+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae5ab741-ddae-4efa-b347-0ce5009767d4", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Storytelling: the closing ask", "slug": "closing-ask", "status": "active", "bestFor": null, "canonId": "019df269-24e0-70ab-8dd9-983832c1c665", "version": 1, "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d", "description": "The single most important slide in the deck — after the cover. The final", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "8dc5ed1c-142d-4bf2-aea4-c9e08bb17563", "evidence": "slide type is closing_ask with headline and image/logo", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:39:13.401599+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 8, "to": 9, "label": "Problem", "description": "Slides 8-9 discuss the role of cytokines in immuno-oncology and their limitations." }, { "from": 12, "to": 20, "label": "Solution", "description": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results." }, { "from": 35, "to": 36, "label": "Financials", "description": "Slides 35-36 provide an overview of Mural Oncology's carve-out financials." } ], "loops": [ { "from": 8, "to": 9, "label": "Cost Of Inaction", "description": "What are the consequences of not addressing the limitations of current cytokine therapies?" }, { "from": 20, "to": 21, "label": "Before After", "description": "How does Nemvaleukin alfa improve treatment outcomes?" } ] }